The NHS is set to accelerate the delivery of the weight-loss drug Mounjaro as part of a significant strategic shift in the 2026/27 GP contract. Announced on 23 February 2026, the new government obesity strategy introduces financial incentives for General Practitioners to move weight management from specialist clinics into local surgeries. This transition aims to address a public health crisis that currently costs the health service an estimated £11 billion (approximately $14.8 billion) annually.
Under the new framework, the Department of Health and Social Care (DHSC) seeks to decentralise treatment by offering bonuses to practices that meet specific prescribing targets. By moving these services into primary care, the government intends to reduce the pressure on hospital-based specialist weight management tiers. The initiative is being positioned as a fundamental change in how the British state manages long-term metabolic health.
